NERV - ミネルバ・ニュ―ロサイエンシズ （Minerva Neurosciences Inc） ミネルバ・ニュ―ロサイエンシズNERVのチャート
NERVの企業情報
| symbol | NERV |
|---|---|
| 会社名 | Minerva Neurosciences Inc （ミネルバ・ニュ―ロサイエンシズ） |
| 分野（sector） | Health Care ヘルスケア |
| 産業（industry） | Major Pharmaceuticals |
| 業種 | バイオテクノロジ―_メディカルリサ―チ 医療関連（Health Care） |
| 概要 | 事業概要 ミネルバ・ニューロサイエンス（Minerva Neurosciences Inc. ）は臨床段階のバイオ医薬品会社である。同社は中枢神経系（CNS）疾患に患う患者を治療するために、製品候補のポートフォリオを開発・商品化する。同社の製品ポートフォリオは統合失調症の治療用MIN-101、不眠症およびうつ病障害（MDD）の治療用MIN-202、MDDの治療用MIN-117及びパーキンソン病の治療用MIN-301を含む。MIN-101は気分、認知、睡眠および不安の調節に関与する脳内の2つの受容体であるセロトニン受容体およびシグマ受容体を遮断する化合物である。MIN-117は5-ヒドロキシトリプタミンタイプ1A（5-HT1A）と呼ばれるセロトニン受容体の特定のサブタイプを遮断する。MIN-202は選択的オレキシン2受容体アンタゴニストである。MIN-301はパーキンソン病の治療のためのニューレグリン-1 1b1（NRG-1b1）タンパク質の可溶性組換え形態である。 ミネルバ・ニュ―ロサイエンシズは、米国のバイオ医薬品会社。中枢神経系(CNS)疾患の患者を治療するため、製品の開発、実用化に注力する。臨床段階にある主要な薬剤候補は、「MIN-101」や「MIN-117」など。統合失調症、大うつ病性障害、不眠症、パ―キンソン病の治療のため、治験薬の開発を行っている。 Minerva's portfolio of compounds includes: roluperidone (MIN-101), in clinical development for schizophrenia, and MIN-301, in pre-clinical development for Parkinson's disease. |
| 本社所在地 | 1601 Trapelo Road Suite 286 Waltham MA 02451 USA |
| 代表者氏名 | Remy Luthringer レミー・ライスリンガー |
| 代表者役職名 | Executive Chairman of the Board Chief Executive Officer |
| 電話番号 | +1 617-600-7373 |
| 設立年月日 | 39173 |
| 市場名 | NASDAQ National Market System |
| ipoyear | 2014年 |
| 従業員数 | 12人 |
| url | www.minervaneurosciences.com |
| nasdaq_url | https://www.nasdaq.com/symbol/nerv |
| adr_tso | ― |
| EBITDA | EBITDA（百万ドル） -46.60467 |
| 終値（lastsale） | 11.17 |
| 時価総額（marketcap） | 433109411.31 |
| 時価総額 | 時価総額（百万ドル） 409.84480 |
| 売上高 | 売上高（百万ドル） 0.00000 |
| 企業価値(EV) | 企業価値(EV)（百万ドル） 302.75407 |
| 当期純利益 | 当期純利益（百万ドル） -45.44626 |
| 決算概要 | 決算概要 BRIEF: For the six months ended 30 June 2018 Minerva Neurosciences Inc revenues was not reported. Net loss increased 22% to $24.9M. Basic Earnings per Share excluding Extraordinary Items decreased from -$0.57 to -$0.64. |
NERVのテクニカル分析
NERVのニュース
Minerva Neurosciences, Inc: Minerva Neurosciences to Report Fiscal Year 2022 Financial Results and Business Updates on March 8, 2023 2023/03/01 13:46:00 Finanz Nachrichten
Management to Host Conference CallBURLINGTON, Mass., March 01, 2023(Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system…
Minerva Neurosciences to Report Fiscal Year 2022 Financial Results and Business Updates on March 8, 2023 2023/03/01 13:30:00 GlobeNewswire
Management to Host Conference Call Management to Host Conference Call
Results from Minerva Neurosciences Inc. (NERV) show risk 2022/12/29 12:00:00 US Post News
The share price of Minerva Neurosciences Inc. (NASDAQ:NERV) fell to $1.43 per share on Wednesday from $2.35. While Minerva Neurosciences Inc. has underperformed by -39.15%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, NERV fell by -79.40%, with highs and lows ranging from $15.27 to $2.21, […]
US stock market closed lower, Dow Jones down 1.10% 2022/12/29 02:17:37 InstaForex
At the close of the New York Stock Exchange, the Dow Jones was down 1.10%, the S&P 500 was down 1.20% and the NASDAQ Composite was down 1.35%. JPMorgan Chase & Co was the top gainer among the components of the Dow Jones in today''s trading, up 0.72 points (0.55%) to close at 132.46. Quotes of Goldman Sachs Group Inc fell by 1.10 points (0.32%) to close at 340.87. Johnson & Johnson shed 0.77 points or 0.43% to close at 176.66. Shares of Apple Inc were the least gainers, the price of which fell by 3.99 points (3.07%), ending the session at 126.04. The Walt Disney Company was up 2.55% or 2.20 points to close at 84.17, while Dow Inc was down 2.34% or 1.20 points to close at 49. 99. Leading gainers among the S&P 500 index components in today''s trading were Generac Holdings Inc, which rose 5.61% to 96.26, Tesla Inc, which gained 3.31% to close at 112.71, and shares of Illumina Inc, which rose 1.08% to end the session at 190.81. The least gainers were SolarEdge Technologies Inc, which shed 5.87% to close at 275.84.
Minerva Neurosciences Plunges after FDA Refusal 2022/12/28 17:13:02 TipRanks
Shares of Minerva Neurosciences (NASDAQ:NERV) plunged by almost one-third in today’s trading session. This can be attributed to the FDA’s decision …
Results from Minerva Neurosciences Inc. (NERV) show risk 2022/12/29 12:00:00 US Post News
The share price of Minerva Neurosciences Inc. (NASDAQ:NERV) fell to $1.43 per share on Wednesday from $2.35. While Minerva Neurosciences Inc. has underperformed by -39.15%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, NERV fell by -79.40%, with highs and lows ranging from $15.27 to $2.21, […]
US stock market closed lower, Dow Jones down 1.10% 2022/12/29 02:17:37 InstaForex
At the close of the New York Stock Exchange, the Dow Jones was down 1.10%, the S&P 500 was down 1.20% and the NASDAQ Composite was down 1.35%. JPMorgan Chase & Co was the top gainer among the components of the Dow Jones in today''s trading, up 0.72 points (0.55%) to close at 132.46. Quotes of Goldman Sachs Group Inc fell by 1.10 points (0.32%) to close at 340.87. Johnson & Johnson shed 0.77 points or 0.43% to close at 176.66. Shares of Apple Inc were the least gainers, the price of which fell by 3.99 points (3.07%), ending the session at 126.04. The Walt Disney Company was up 2.55% or 2.20 points to close at 84.17, while Dow Inc was down 2.34% or 1.20 points to close at 49. 99. Leading gainers among the S&P 500 index components in today''s trading were Generac Holdings Inc, which rose 5.61% to 96.26, Tesla Inc, which gained 3.31% to close at 112.71, and shares of Illumina Inc, which rose 1.08% to end the session at 190.81. The least gainers were SolarEdge Technologies Inc, which shed 5.87% to close at 275.84.
Minerva Neurosciences Plunges after FDA Refusal 2022/12/28 17:13:02 TipRanks
Shares of Minerva Neurosciences (NASDAQ:NERV) plunged by almost one-third in today’s trading session. This can be attributed to the FDA’s decision …
Minerva Falls After FDA Rejects NDA For Roluperidone For Treatment Of Schizophrenia 2022/12/28 15:21:33 RTT News
Minerva Neurosciences, Inc. (NERV) shares are sliding more than 17 percent on Wednesday morning trade after the company said it is disappointed to announce that the FDA has confirmed the refuse to file letter dated October 14, 2022 remains in effect in respect of the NDA for Roluperidone for the treatment of negative symptoms of schizophrenia.
Kala, Cosmos top healthcare gainers; Minerva, HTG Molecular among losers 2022/12/28 15:00:16 Seeking Alpha
Kala Pharmaceuticals (KALA) +116%. Cosmos (COSM) +20%. Minerva Neurosciences NERV -16%. HTG Molecular Diagnostics (HTGM) -10%.
Minerva Neurosciences, Inc: Minerva Neurosciences Reports Second Quarter 2021 Financial Results and Business Updates 2021/08/02 11:41:00 FinanzNachrichten
WALTHAM, Mass., Aug. 02, 2021 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central ner
Minerva Neurosciences Reports Second Quarter 2021 Financial Results and Business Updates 2021/08/02 11:30:00 Intrado Digital Media
WALTHAM, Mass., Aug. 02, 2021 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today reported key business updates and financial results for the quarter ended June 30, 2021.
The Daily Biotech Pulse: ObsEva Surges On Out-Licensing Deal, EyeGate Appoints New CEO, 2 Positive Catalysts For Merck, Candel Therapeutics Debuts 2021/07/27 11:48:32 Benzinga
Here''s a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 26) Absci, CORP (NASDAQ: ABSI ) (IPOed Thursday) Arvinas, Inc. (NASDAQ: ARVN ) BioNTech SE (NASDAQ: BNTX ) ( disclosed plans to make mRNA vaccine for malaria by 2022) Cassava Sciences, Inc. (NASDAQ: SAVA ) (announced positive data for SavaDx, an investigational diagnostic/biomarker to detect Alzheimer''s disease with a simple blood test) Eli Lilly and Company (NYSE: LLY ) Moderna, Inc. (NASDAQ: MRNA ) Monte Rosa Therapeutics, Inc. (NASDAQ: GLUE ) NanoVibronix, Inc. (NASDAQ: NAOV ) (announced first shipment of its next generation pain management device, PainShield Plus) Oramed Pharmaceuticals Inc. (NASDAQ: ORMP ) Sight Sciences, Inc. (NASDAQ: SGHT ) (IPOed July 15) Translate Bio, Inc. (NASDAQ: TBIO ) (moved on positive analyst action) Down In The Dumps (Biotech Stocks Hitting 52-week Lows July 26) 23andMe Holding Co. (NASDAQ: ME ) AbCellera Biologics Inc.